JP2005097320A5 - - Google Patents

Download PDF

Info

Publication number
JP2005097320A5
JP2005097320A5 JP2004362085A JP2004362085A JP2005097320A5 JP 2005097320 A5 JP2005097320 A5 JP 2005097320A5 JP 2004362085 A JP2004362085 A JP 2004362085A JP 2004362085 A JP2004362085 A JP 2004362085A JP 2005097320 A5 JP2005097320 A5 JP 2005097320A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004362085A
Other languages
Japanese (ja)
Other versions
JP2005097320A (ja
Filing date
Publication date
Priority claimed from US08/035,443 external-priority patent/US6326353B1/en
Application filed filed Critical
Publication of JP2005097320A publication Critical patent/JP2005097320A/ja
Publication of JP2005097320A5 publication Critical patent/JP2005097320A5/ja
Abandoned legal-status Critical Current

Links

JP2004362085A 1993-03-23 2004-12-14 増強循環エフェクター組成物および方法 Abandoned JP2005097320A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/035,443 US6326353B1 (en) 1993-03-23 1993-03-23 Enhanced circulation effector composition and method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP6521332A Division JPH08508256A (ja) 1993-03-23 1994-03-22 増強循環エフェクター組成物および方法

Publications (2)

Publication Number Publication Date
JP2005097320A JP2005097320A (ja) 2005-04-14
JP2005097320A5 true JP2005097320A5 (enExample) 2005-10-27

Family

ID=21882712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP6521332A Pending JPH08508256A (ja) 1993-03-23 1994-03-22 増強循環エフェクター組成物および方法
JP2004362085A Abandoned JP2005097320A (ja) 1993-03-23 2004-12-14 増強循環エフェクター組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP6521332A Pending JPH08508256A (ja) 1993-03-23 1994-03-22 増強循環エフェクター組成物および方法

Country Status (10)

Country Link
US (1) US6326353B1 (enExample)
EP (1) EP0689428B1 (enExample)
JP (2) JPH08508256A (enExample)
AT (1) ATE175868T1 (enExample)
AU (1) AU6368494A (enExample)
CA (1) CA2157410C (enExample)
DE (1) DE69416116T2 (enExample)
DK (1) DK0689428T3 (enExample)
ES (1) ES2131190T3 (enExample)
WO (1) WO1994021235A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
GB9509016D0 (en) * 1995-05-03 1995-06-21 Royal Free Hosp School Med Tissue entrapment
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
ES2615357T3 (es) 1996-12-06 2017-06-06 Amgen Inc. Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL131406A0 (en) 1997-02-21 2001-01-28 Genentech Inc Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
DE69922189T2 (de) 1998-04-27 2005-11-10 Opperbas Holding B.V. Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
MXPA03008864A (es) * 2001-03-26 2004-12-06 Johnson & Johnson Composicion de liposoma para el suministro intracelular mejorado en un agente terapeutico.
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
MXPA04008419A (es) * 2002-03-01 2004-11-26 Univ Tulane Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos.
ME00204B (me) 2002-09-06 2011-02-10 Medarex Llc Terapijsko, humano, monoklonsko anti-il-1r1antitijelo
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1587484A4 (en) * 2002-12-19 2008-11-12 Alza Corp METHOD OF TREATING ANGIOGENIC TISSUE GROWTH
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP1617808A4 (en) 2003-04-25 2011-11-02 Penn State Res Found METHOD AND SYSTEM FOR THE SYSTEMIC DISTRIBUTION OF GROWTH-INHIBITORS OF LIPID-DERIVED BIOACTIVE COMPOUNDS
JP2007501811A (ja) * 2003-08-08 2007-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。
WO2006042270A1 (en) * 2004-10-08 2006-04-20 Alza Corporation Method of inserion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20070014845A1 (en) * 2005-07-01 2007-01-18 Yuanpeng Zhang Liposomal delivery vehicle for hydrophobic drugs
US20070055199A1 (en) 2005-08-10 2007-03-08 Gilbert Scott J Drug delivery device for buccal and aural applications and other areas of the body difficult to access
JP2009507919A (ja) * 2005-09-12 2009-02-26 アルザ・コーポレーシヨン 多発性骨髄腫を処置するためのリポソーム
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
WO2007133627A2 (en) * 2006-05-10 2007-11-22 Alza Corporation Method for making liposomes conjugated with temperature-sensitive ligands
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CN101918018B (zh) 2007-11-14 2012-12-05 再生医药有限公司 使用白介素-1受体拮抗剂作为骨髓保护剂的方法
MY171292A (en) * 2008-12-22 2019-10-07 Creabilis S A Synthesis of polymer conjugates of indolocarbazole compounds
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
TWI397428B (zh) * 2009-12-29 2013-06-01 Ind Tech Res Inst 標的第四介白素受體之傳輸系統
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2679236A1 (de) * 2012-06-29 2014-01-01 Zentrum für biomedizinische Technologie der Donau- Universität Krems Dosierungsanleitung für endotoxinbindende Lipopeptide
WO2014050509A1 (ja) * 2012-09-25 2014-04-03 テルモ株式会社 リポソームおよびリポソーム製剤
EP2983721B2 (en) 2013-04-12 2021-01-20 Evox Therapeutics Limited Therapeutic delivery vesicles
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
CN111217993B (zh) * 2018-11-26 2022-05-20 沈阳药科大学 一种聚乙二醇化酚红及其制备方法和用途
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4948590A (en) * 1987-06-09 1990-08-14 Yale University Avidin or streptavidin conjugated liposomes
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1992014448A1 (en) * 1991-02-14 1992-09-03 Baxter International Inc. Binding of growth hormone to liposomes
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム

Similar Documents

Publication Publication Date Title
BE2024C508I2 (enExample)
BE2023C542I2 (enExample)
BE2022C549I2 (enExample)
BE2021C001I2 (enExample)
BE2020C513I2 (enExample)
BE2020C517I2 (enExample)
BE2019C540I2 (enExample)
BE2019C523I2 (enExample)
BE2019C548I2 (enExample)
BE2019C506I2 (enExample)
BE2018C045I2 (enExample)
BE2020C525I2 (enExample)
BE2017C063I2 (enExample)
BE2017C027I2 (enExample)
BE2017C023I2 (enExample)
BE2017C002I2 (enExample)
BE2016C067I2 (enExample)
BE2016C014I2 (enExample)
BE2015C041I2 (enExample)
BE2015C038I2 (enExample)
BE2015C014I2 (enExample)
BE2014C071I2 (enExample)
BE2015C015I2 (enExample)
BE2014C064I2 (enExample)
BE2014C063I2 (enExample)